GERN logo

GERN Geron Corporation

NASDAQ Global Select · Biotechnology · Healthcare

$0.99
-0.01 (-0.91%)

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hemat…

Market Cap: $638.38Mwww.geron.com

Price

No data yet.

Social Signal Score

41
5d
30
1 mentions
—
30d
45
6 mentions
—
60d
45
9 mentions
—
90d
45
13 mentions
—
news: 13

Analyst Ratings

22 analysts
Buyconsensus
Strong Buy 0Buy 15Hold 7Sell 0Strong Sell 0
Avg price target$5.89+494.4%
Low $4Median $6High $8
Current Consensus

Revenue

$60.19M+63931.91%
$21.0K$20.08M$40.13M$60.19M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.10
$-0.12–$-0.09
3 analysts
FY2026
$-0.02
$-0.04–$-0.01
2 analysts
FY2027
$0.09
$0.04–$0.17
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Harout Semerjian
Sector
Healthcare
Industry
Biotechnology
Employees
258
Beta
0.61
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-2.55
www.geron.com